Ashford Capital Management Inc. Sells 612,840 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Ashford Capital Management Inc. reduced its stake in Cellebrite DI Ltd. by 33.1%, making up approximately 3.1% of its portfolio, while also indicating it remains the firm's 9th largest holding.
• Institutional investments in Cellebrite DI have varied, with NewEdge Advisors increasing its position by 600.7%, while other firms like Northern Trust Corp and AQR Capital Management also purchased new stakes in the company.
• Analysts have mixed ratings on Cellebrite DI, with some lowering price targets while Wall Street Zen upgraded it to a "buy" rating, and the stock currently has an average rating of "buy" with a consensus price target of $22.40.

Ashford Capital Management Inc. decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,237,840 shares of the company's stock after selling 612,840 shares during the period. Cellebrite DI makes up approximately 3.1% of Ashford Capital Management Inc.'s holdings, making the stock its 9th biggest position. Ashford Capital Management Inc. owned 0.52% of Cellebrite DI worth $24,051,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. bought a new position in shares of Cellebrite DI in the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC bought a new position in shares of Cellebrite DI in the first quarter valued at approximately $51,000. Virtus Advisers LLC bought a new position in shares of Cellebrite DI in the first quarter valued at approximately $63,000. Gen Wealth Partners Inc bought a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $85,000. Finally, NewEdge Advisors LLC boosted its holdings in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. Institutional investors own 45.88% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Finally, Lake Street Capital cut their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT traded up $0.20 during mid-day trading on Thursday, hitting $16.71. The stock had a trading volume of 1,009,238 shares, compared to its average volume of 1,676,483. The company has a market cap of $4.00 billion, a PE ratio of -21.96, a P/E/G ratio of 2.98 and a beta of 1.28. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The company's 50 day moving average is $15.01 and its 200-day moving average is $17.09.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.